Last reviewed · How we verify
autologous cord blood mononuclear cells — Competitive Intelligence Brief
phase 3
Regenerative Medicine
Biologic
Live · refreshed every 30 min
Target snapshot
autologous cord blood mononuclear cells (autologous cord blood mononuclear cells) — Guangdong Women and Children Hospital. Autologous cord blood mononuclear cells are used to stimulate the body's natural repair processes.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| autologous cord blood mononuclear cells TARGET | autologous cord blood mononuclear cells | Guangdong Women and Children Hospital | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- autologous cord blood mononuclear cells CI watch — RSS
- autologous cord blood mononuclear cells CI watch — Atom
- autologous cord blood mononuclear cells CI watch — JSON
- autologous cord blood mononuclear cells alone — RSS
Cite this brief
Drug Landscape (2026). autologous cord blood mononuclear cells — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-cord-blood-mononuclear-cells. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab